RRx-001 Emerging Drug Insight

“RRx-001 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about RRx-001 for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the RRx-001 for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the RRx-001 for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RRx-001 market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

RRx-001, a first-in-class immunostimulatory agent, which contains a novel dinitroazetidine pharmacophore, was in-sourced from a major aerospace contractor, ATK-Orbital, on the initial assumption that it would deplete cellular glutathione, the principal scavenger of reactive oxygen/nitrogen species, thereby inducing the formation of free radicals and sensitizing hypoxic cells to the ionizing effects of radiation. This assumption was based on evidence of the covalent binding of RRx-001 to reduced glutathione and the presence of geminal dinitro- groups in the four-membered azetidine ring of the molecule; these dinitro- groups were hypothesized to decompose in vivo under hypoxic conditions, producing the gaseous free radical, nitric oxide. However, as it turned out, the mechanism is more involved than reduced thiol depletion or nitric oxide radical-induced radiosensitization, even though reactive oxygen and nitrogen species were subsequently found to play prominent roles as M1 activators of tumor-associated macrophages, which, in turn, mediate oxidant injury to the cancer cells and the cancer stroma.

RRx-001 is a first-in-class aerospace-based therapeutic that has been evaluated in global clinical trials that have demonstrated both selective antitumor activity in several cancer types, including metastatic colorectal cancer (CRC), as a single agent, as a radiochemosensitizer, and as an immunosensitizer.

RRx-001 plus irinotecan significantly improved progression-free survival (PFS) versus regorafenib in the randomized Phase II ROCKET trial in advanced colorectal cancer.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the RRx-001 description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on RRx-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RRx-001 research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RRx-001.
• The report contains forecasted sales of RRx-001 for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for RRx-001 in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

RRx-001 Analytical Perspective by DelveInsight

In-depth RRx-001 Market Assessment

This report provides a detailed market assessment of RRx-001 in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

RRx-001 Clinical Assessment

The report provides the clinical trials information of RRx-001 in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RRx-001 dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to RRx-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RRx-001 in Metastatic Colorectal Cancer.
• Our in-depth analysis of the forecasted sales data of RRx-001 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RRx-001 in Metastatic Colorectal Cancer.

Key Questions

• What is the product type, route of administration and mechanism of action of RRx-001?
• What is the clinical trial status of the study related to RRx-001 in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RRx-001 development?
• What are the key designations that have been granted to RRx-001 for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of RRx-001 for Metastatic Colorectal Cancer?
• What are the forecasted sales of RRx-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to RRx-001 for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?